The S&P/ASX 200 Index (ASX: XJO) is having another positive session on Wednesday. At the time of writing, the benchmark index is up 0.2% to 8,086.6 points.
Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:
Image source: Getty Images
Cedar Woods Properties Ltd (ASX: CWP)
The Cedar Woods share price is up 5% to $5.49. This follows the release of the property developer's quarterly update. Cedar Woods had a stronger than expected quarter and has upgraded its guidance for FY 2025. It has now increased its net profit after tax guidance to 15% from a minimum of 10%. The good news is that management advised that "further strong profit growth is anticipated in FY26, with the company having secured significant presales of the product expected to settle in that financial year."
Orthocell Ltd (ASX: OCC)
The Orthocell share price is up 13% to $1.66. Investors have been buying this regenerative medicine company's shares after it received regulatory approval in another country. Orthocell has been granted a Medical Device Licence (MDL) by Health Canada to allow sales of its Remplir product to commence into the US$75 million Canadian nerve repair market. Remplir is a collagen wrap used in nerve repair surgery to assist surgeons to improve outcomes in the repair and regeneration of damaged nerves.
PEXA Group Ltd (ASX: PXA)
The PEXA Group share price is up 5% to $12.00. This morning, this property settlement technology company announced that the UK's Financial Conduct Authority (FCA) has approved PEXA's application to become an Authorised Payment Institution (API), which is required to launch the source account capability within PEXA's UK Sale & Purchase product offering. PEXA CEO, Russell Cohen, said: "The FCA approval of our API application is a key component of our UK strategy, most notably the launch of the Sale & Purchase product."
St Barbara Ltd (ASX: SBM)
The St Barbara Ltd share price is up 8% to 29.2 cents. This morning, this gold miner released the outcomes of its Simberi Process Plant Study and the inclusion of updated mineral resource and ore reserve estimates. CEO Andrew Strelein said: "Our current work shows a project with significantly higher production averaging 220 kozpa over eight years, a lower operating cost and a mine life extending to 13 years without including any exploration targets. At an assumed gold price of only US$2500/oz that delivers a Post-Tax NPV (8%) of US$717 million and a Post-Tax IRR of 62%."
